SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001411685-24-000039
Filing Date
2024-08-13
Accepted
2024-08-13 16:53:06
Documents
15
Period of Report
2024-08-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vtgn-20240813.htm   iXBRL 8-K 25655
2 EX-99.1 vtgn-20240813xex991.htm EX-99.1 82382
6 image01.jpg GRAPHIC 4984
  Complete submission text file 0001411685-24-000039.txt   249689

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vtgn-20240813.xsd EX-101.SCH 1904
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vtgn-20240813_lab.xml EX-101.LAB 21629
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vtgn-20240813_pre.xml EX-101.PRE 12510
17 EXTRACTED XBRL INSTANCE DOCUMENT vtgn-20240813_htm.xml XML 2729
Mailing Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-577-3600
Vistagen Therapeutics, Inc. (Filer) CIK: 0001411685 (see all company filings)

IRS No.: 205093315 | State of Incorp.: NV | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-37761 | Film No.: 241202545
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)